Summary

The global transfection technologies market is expected to grow at a significant rate of around 8% during the forecast period. An approach to introducing exogenous nucleic acids like RNA, DNA, or oligonucleotides into cells is known as transfection. This technique is frequently used in genomic research, but it can also be used for bio-production or medicinal purposes. In addition, cell research is the major key factor for the transfection technologies market as more than 60% of the users are from academic institutions and researchers. Research in gene transfer is being performed in in-vivo conditions for various therapeutic applications, there is high demand for new & advanced technologies to match the needs for therapeutic delivery which will drive the market growth during the forecast period.

Moreover, the rising mortality rates and hospital admissions are primarily due to the spread of chronic diseases and viral infections. People are becoming more prone to such diseases as immunity decreases. For instance, according to the Centers for Disease Control and Prevention (CDC), six in ten adults in the U.S. have chronic diseases and four in ten adults have two or more.

Lonza Group Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Roche, QIAGEN, Mirus Bio LLC, SignaGen Laboratories, Genlantis Inc., OZ Biosciences, and Promega Corporation are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report
“Amongst product type, reagent category to witness robust CAGR during the forecast period”
Based on product type, the market is segmented into reagents, instruments, and others. The reagent category is to witness a higher CAGR during the forecast period owing to the growing adoption of reagent-based methods. In comparison to the traditionally used techniques, reagent-based transfection is less complicated to administer and more cost-effective. Furthermore, product development and its less complicated methods are involved during the transfection. For Instance, in 2022, Polypus, a provider of transfection reagents acquired e-Zyvec, a France-based provider of DNA design and production services for custom-made DNA vectors to expand their expertise in plasmid DNA vector engineering.

“Amongst technology, the viral-vector-based transfection to hold a significant share in the market in 2021”
On the basis of technology, the market is categorized into physical transfection, biochemical-based transfection, and viral-vector-based transfection. Among these, the viral-vector-based transfection to hold a significant share in the market in 2021. This is mainly due to the high preciseness of the viral vector as compared to gene transduction as virus-mediated transfection makes use of a viral vector to deliver DNA and RNA into the cells. Moreover, viral vector in transduction extends the advantages of easy permeability in cells that are quite rigid to bisect making it easy to accomplish transgene countenance in vivo.

“North America to hold a significant share in the market”
For a better understanding of the market adoption of the transfection technologies market, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period owing to the presence of leading pharmaceutical companies and cutting-edge research labs that regularly contribute to research and development. States in North America are compelled to spend an incalculable amount of money developing cutting-edge treatments due to their full-fledged economies. Additionally, this sector's dominance in the transfection technologies market is primarily attributable to the rising rates of obesity and breast cancer in the United States. For instance, according to the Centers for Disease Control and Prevention (CDC), the obesity prevalence was 39.8% among adults aged 20 to 39 years, 44.3% among adults aged 40 to 59 years, and 41.5% among adults aged 60 and older.

Reasons to buy this report:
• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.

Customization Options:
The global transfection technologies market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect us to get a report that completely suits your requirements.

ページTOPに戻る

Table of Contents